Setting and Participants
EPT, gonorrhea, chlamydia
TRICHOMONIASIS, GONORRHEA
The pilot study was conducted between August–October 2021 at an academic ED in the midwestern US with a patient volume of over 100,000 visits per year. In Michigan, EPT is legal and encouraged by the Michigan Department of Health and Human Services (MDHHS) for chlamydia, gonorrhea, and trichomoniasis.The MDHHS obtained these medications from a pharmacy distributor and repackaged them into pre-labeled kits with information and instructions for EPT. To abide by drug safety regulations regarding the transfer of medications, a T3 document in which a drug manufacturer details all product information to a new recipient, was obtained and approved by the ED pharmacy. The take-home kits were then delivered to the ED in packages for either potentially pregnant (containing cefixime and azithromycin) or not pregnant (containing cefixime and doxycycline) patients. Pregnancy status was based on ED serum or urine testing. This study was approved by the study site’s institutional review board (HUM00199376) and (HUM00196451).